Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:CLSN
- CUSIP: N/A
- Web: www.celsion.com
Capitalization:- Market Cap: $13.03 million
- Outstanding Shares: 8,351,000
Average Prices:- 50 Day Moving Avg: $1.40
- 200 Day Moving Avg: $1.20
- 52 Week Range: $0.19 - $4.96
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.50
- P/E Growth: 0.0000
Sales & Book Value:- Annual Revenue: $500,000.00
- Price / Sales: 26.06
- Book Value: $1.12 per share
- Price / Book: 1.39
Profitability:- EBIDTA: ($18,990,000.00)
- Net Margins: -4,440.60%
- Return on Equity: -276.51%
- Return on Assets: -64.50%
Debt:- Current Ratio: 0.54%
- Quick Ratio: 0.54%
Misc:- Average Volume: 623,419 shs.
- Beta: 1
- Short Ratio: 0.5
Frequently Asked Questions for Celsion Corporation (NASDAQ:CLSN)
What is Celsion Corporation's stock symbol?
Celsion Corporation trades on the NASDAQ under the ticker symbol "CLSN."
When did Celsion Corporation's stock split? How did Celsion Corporation's stock split work?
Shares of Celsion Corporation reverse split on the morning of Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Celsion Corporation stock prior to the reverse split would have 7 shares after the split.
How were Celsion Corporation's earnings last quarter?
Celsion Corporation (NASDAQ:CLSN) posted its quarterly earnings results on Thursday, May, 18th. The company reported ($1.64) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.30) by $0.34. The business earned $0.13 million during the quarter, compared to analyst estimates of $0.13 million. Celsion Corporation had a negative return on equity of 276.51% and a negative net margin of 4,440.60%. View Celsion Corporation's Earnings History.
When will Celsion Corporation make its next earnings announcement?
Where is Celsion Corporation's stock going? Where will Celsion Corporation's stock price be in 2017?
3 analysts have issued 12 month price objectives for Celsion Corporation's stock. Their forecasts range from $21.00 to $56.00. On average, they anticipate Celsion Corporation's stock price to reach $32.67 in the next year. View Analyst Ratings for Celsion Corporation.
What are analysts saying about Celsion Corporation stock?
Here are some recent quotes from research analysts about Celsion Corporation stock:
- 1. According to Zacks Investment Research, "Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. " (8/29/2017)
- 2. Maxim Group analysts commented, "Celsion announced that the company will present updated data from the P1b Ovation study evaluating GEN-1 (DNA-based IL-12) in advanced ovarian cancer at ASCO (American Society of Clinical Oncology, June 2-6, 2017)." (4/20/2017)
Who are some of Celsion Corporation's key competitors?
Some companies that are related to Celsion Corporation include Aviragen Therapeutics (AVIR), Heat Biologics (HTBX), Biopharmx Corp (BPMX), Biopharmx Corp (BPMX), Biopharmx Corp (BPMX), Xenetic Biosciences (XBIO), Cerulean Pharma (DARE), Anthera Pharmaceuticals (ANTH), Evgen Pharma PLC (EVG), Proteome Sciences plc (PRM), Kitov Pharmaceuticals Holdings (KTOV), Ritter Pharmaceuticals (RTTR), Opexa Therapeutics (ACER), ValiRx Plc (VAL), Ariad Pharmaceuticals (ARIA), Auspex Pharmaceuticals (ASPX), Biotie Therapies Corp (BITI) and Cynapsus Therapeutics (CYNA).
Who are Celsion Corporation's key executives?
Celsion Corporation's management team includes the folowing people:
- Jeffrey Wayne Church CPA, Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer
- Khursheed Anwer Ph.D., Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
- Nicholas Borys M.D., Senior Vice President and Chief Medical Officer
- Michael H. Tardugno, Executive Chairman of the Board, President, Chief Executive Officer
- Donald Braun Ph.D., Independent Director
- Pok Yu Chow Ph.D., Independent Director
- Frederick J. Fritz, Independent Director
- Robert W. Hooper, Independent Director
- Alberto R. Martinez M.D., Independent Director
Who owns Celsion Corporation stock?
Celsion Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include
ANSON FUNDS MANAGEMENT LP
(9.60%),
INTRACOASTAL CAPITAL, LLC
(8.30%),
INTRACOASTAL CAPITAL, LLC
(1.90%), Vanguard Group Inc. (2.28%),
INTRACOASTAL CAPITAL, LLC
(1.50%) and Virtu KCG Holdings LLC (1.24%). Company insiders that own Celsion Corporation stock include Alberto R Martinez Jr, Egwu, Inc Fka Egen, Inc, Frederick J Fritz and Michael H Tardugno. View Institutional Ownership Trends for Celsion Corporation.
Who sold Celsion Corporation stock? Who is selling Celsion Corporation stock?
How do I buy Celsion Corporation stock?
Shares of Celsion Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celsion Corporation's stock price today?
One share of Celsion Corporation stock can currently be purchased for approximately $1.56.
MarketBeat Community Rating for Celsion Corporation (NASDAQ CLSN)MarketBeat's community ratings are surveys of what our community members think about Celsion Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Celsion Corporation (NASDAQ:CLSN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $32.67 (1,994.02% upside) |
Analysts' Ratings History for Celsion Corporation (NASDAQ:CLSN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/15/2017 | Maxim Group | Reiterated Rating | Hold | | Medium |  |
| 4/10/2017 | Rodman & Renshaw | Reiterated Rating | Buy | $21.00 | High | |
| 4/10/2017 | HC Wainwright | Reiterated Rating | Buy | $21.00 | High | |
| 11/24/2015 | Cantor Fitzgerald | Reiterated Rating | Not Available -> Buy | | N/A | |
(Data available from 9/26/2015 forward)
Earnings History for Celsion Corporation (NASDAQ:CLSN)Earnings History by Quarter for Celsion Corporation (NASDAQ CLSN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/9/2017 | | | | | | | | |
| 5/18/2017 | Q1 2017 | ($1.30) | ($1.64) | $0.13 million | $0.13 million | View | N/A | |
| 3/16/2017 | Q4 2016 | ($2.24) | ($1.96) | $0.13 million | $0.13 million | View | N/A | |
| 11/10/2016 | Q3 2016 | ($2.66) | ($3.22) | $0.13 million | $0.13 million | View | N/A | |
| 8/15/2016 | Q2 | ($2.94) | ($2.66) | $0.13 million | $0.13 million | View | Listen | |
| 5/16/2016 | Q116 | ($2.94) | ($3.36) | $0.13 million | $0.13 million | View | Listen | |
| 3/30/2016 | Q415 | ($3.36) | ($3.36) | $0.16 million | $0.13 million | View | Listen | |
| 11/5/2015 | Q315 | ($3.64) | ($2.80) | $0.14 million | $0.13 million | View | N/A | |
| 8/10/2015 | Q215 | ($4.34) | ($3.78) | $0.16 million | $0.13 million | View | Listen | |
| 5/12/2015 | Q1 | ($4.62) | ($4.76) | $0.13 million | $0.13 million | View | N/A | |
| 3/12/2015 | Q4 2014 | ($5.04) | ($4.48) | $0.13 million | $0.13 million | View | N/A | |
| 11/11/2014 | Q3 2014 | ($4.20) | ($4.90) | $0.16 million | $0.13 million | View | N/A | |
| 8/7/2014 | Q214 | ($3.92) | ($4.48) | $0.13 million | $0.13 million | View | N/A | |
| 5/8/2014 | Q1 2014 | ($2.80) | ($4.62) | $0.13 million | $0.13 million | View | N/A | |
| 3/13/2014 | | ($3.92) | ($2.66) | | | View | N/A | |
| 11/12/2013 | Q3 | ($3.15) | ($4.20) | | $0.13 million | View | Listen | |
| 8/8/2013 | Q2 2013 | ($0.98) | $0.14 | | $0.13 million | View | N/A | |
| 5/9/2013 | Q1 2013 | ($2.24) | ($1.68) | | | View | N/A | |
| 11/12/2012 | Q312 | ($2.38) | ($2.52) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Celsion Corporation (NASDAQ:CLSN)2017 EPS Consensus Estimate: ($0.98)
2018 EPS Consensus Estimate: ($1.06)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.08) | ($0.08) | ($0.08) |
| Q2 2017 | 1 | ($0.08) | ($0.08) | ($0.08) |
| Q3 2017 | 1 | ($0.43) | ($0.43) | ($0.43) |
| Q4 2017 | 1 | ($0.39) | ($0.39) | ($0.39) |
| Q1 2018 | 1 | ($0.32) | ($0.32) | ($0.32) |
| Q2 2018 | 1 | ($0.24) | ($0.24) | ($0.24) |
| Q3 2018 | 1 | ($0.25) | ($0.25) | ($0.25) |
| Q4 2018 | 1 | ($0.25) | ($0.25) | ($0.25) |
(Data provided by Zacks Investment Research)
Dividend History for Celsion Corporation (NASDAQ:CLSN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Celsion Corporation (NASDAQ:CLSN)Insider Ownership Percentage: 3.80%
Institutional Ownership Percentage: 7.47%
Insider Trades by Quarter for Celsion Corporation (NASDAQ:CLSN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/7/2017 | Frederick J Fritz | Director | Buy | 13,000 | $1.89 | $24,570.00 | |
| 2/21/2017 | Alberto R Martinez Jr | Director | Buy | 35,000 | $0.23 | $8,050.00 | |
| 2/15/2017 | Alberto R Martinez Jr | Director | Buy | 45,000 | $0.22 | $9,900.00 | |
| 11/14/2016 | Alberto R Martinez Jr | Director | Buy | 10,000 | $0.86 | $8,600.00 | |
| 11/11/2016 | Alberto R Martinez Jr | Director | Buy | 10,000 | $0.91 | $9,100.00 | |
| 10/7/2016 | Michael H Tardugno | Chairman | Buy | 10,000 | $1.14 | $11,400.00 | |
| 8/16/2016 | Alberto R Martinez Jr | Director | Buy | 5,000 | $1.25 | $6,250.00 | |
| 6/17/2016 | Alberto R Martinez Jr | Director | Buy | 5,000 | $1.35 | $6,750.00 | |
| 6/16/2016 | Michael H Tardugno | CEO | Buy | 7,500 | $1.35 | $10,125.00 | |
| 2/19/2016 | Michael H Tardugno | CEO | Buy | 3,000 | $1.27 | $3,810.00 | |
| 2/17/2016 | Michael H Tardugno | CEO | Buy | 2,000 | $1.27 | $2,540.00 | |
| 2/16/2016 | Alberto R Martinez Jr | Director | Buy | 5,000 | $1.16 | $5,800.00 | |
| 2/16/2016 | Michael H Tardugno | CEO | Buy | 4,500 | $1.20 | $5,400.00 | |
| 2/12/2016 | Michael H Tardugno | CEO | Buy | 6,500 | $1.13 | $7,345.00 | |
| 12/3/2015 | Egwu, Inc. Fka Egen, Inc. | Major Shareholder | Sell | 5,556 | $2.08 | $11,556.48 | |
| 11/30/2015 | Egwu, Inc. Fka Egen, Inc. | Major Shareholder | Sell | 20,000 | $2.15 | $43,000.00 | |
| 9/8/2015 | Egwu, Inc. Fka Egen, Inc. | Major Shareholder | Sell | 10,000 | $2.11 | $21,100.00 | |
| 8/17/2015 | Egwu, Inc. Fka Egen, Inc. | Major Shareholder | Sell | 10,000 | $2.19 | $21,900.00 | |
| 8/13/2015 | Egwu, Inc. Fka Egen, Inc. | Major Shareholder | Sell | 20,000 | $2.23 | $44,600.00 | |
| 5/13/2015 | Alberto R Martinez Jr | Director | Buy | 5,000 | $2.50 | $12,500.00 | |
| 12/18/2014 | Frederick J Fritz | Director | Buy | 4,000 | $2.34 | $9,360.00 | |
| 11/13/2014 | Robert W Hooper | Director | Buy | 4,000 | $2.50 | $10,000.00 | |
| 8/15/2014 | Alberto R Martinez Jr | Director | Buy | 5,000 | $3.12 | $15,600.00 | |
| 8/15/2014 | Michael H Tardugno | CEO | Buy | 4,000 | $3.12 | $12,480.00 | |
| 8/14/2014 | Frederick J Fritz | Director | Buy | 4,000 | $3.20 | $12,800.00 | |
| 6/26/2014 | Alberto R Martinez Jr | Director | Buy | 5,000 | $3.36 | $16,800.00 | |
| 6/11/2014 | Michael H Tardugno | CEO | Buy | 5,000 | $3.20 | $16,000.00 | |
| 3/14/2014 | Frederick Fritz | Director | Buy | 2,500 | $3.86 | $9,650.00 | |
| 3/14/2014 | Michael Tardugno | CEO | Buy | 4,000 | $3.84 | $15,360.00 | |
| 11/19/2013 | Michael Tardugno | CEO | Buy | 2,800 | $3.59 | $10,052.00 | |
| 11/15/2013 | Frederick Fritz | Director | Buy | 3,000 | $3.80 | $11,400.00 | |
| 8/16/2013 | Frederick Fritz | Director | Buy | 10,000 | $1.09 | $10,900.00 | |
| 8/16/2013 | Michael Tardugno | CEO | Buy | 5,000 | $1.08 | $5,400.00 | |
| 6/12/2013 | Michael H Tardugno | CEO | Buy | 10,000 | $1.35 | $13,500.00 | |
| 5/21/2013 | Alberto R Martinez Jr | Director | Buy | 5,000 | $0.93 | $4,650.00 | |
| 5/13/2013 | Alberto R Martinez Jr | Director | Buy | 5,000 | $0.96 | $4,800.00 | |
| 5/10/2013 | Alberto R Martinez Jr | Director | Buy | 5,000 | $0.92 | $4,600.00 | |
| 3/20/2013 | Alberto R Martinez Jr | Director | Buy | 3,750 | $1.06 | $3,975.00 | |
| 12/10/2012 | Max Link | Director | Buy | 14,000 | $7.60 | $106,400.00 | |
| 11/15/2012 | Robert W Hooper | Director | Buy | 11,600 | $5.20 | $60,320.00 | |
| 9/14/2012 | Michael H Tardugno | CEO | Buy | 5,000 | $5.03 | $25,150.00 | |
| 9/10/2012 | Robert W Hooper | Director | Buy | 10,000 | $4.95 | $49,500.00 | |
| 8/29/2012 | Robert W Hooper | Director | Buy | 2,500 | $4.65 | $11,625.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Celsion Corporation (NASDAQ:CLSN)
Latest Headlines for Celsion Corporation (NASDAQ:CLSN)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to Celsion Corp. : September 18, 2017
finance.yahoo.com - September 18 at 10:24 PM |
| Stocks Near 52-Week Lows: 4 Attractive Picks
finance.yahoo.com - September 8 at 5:42 PM |
| Stocks Near 52-Week Lows: 4 Attractive Picks
finance.yahoo.com - September 8 at 5:42 PM |
 | Celsion Corporation (CLSN) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - September 3 at 5:52 PM |
| ETFs with exposure to Celsion Corp. : August 31, 2017
finance.yahoo.com - August 31 at 10:13 PM |
| Zacks Investment Research Upgrades Celsion Corporation (CLSN) to Buy
www.americanbankingnews.com - August 29 at 8:56 PM |
 | Celsion Announces Presentation of OVATION Study Findings at the Upcoming AACR Special Conference - GlobeNewswire (press release)
globenewswire.com - August 24 at 10:27 PM |
| Celsion Announces Presentation of OVATION Study Findings at the Upcoming AACR Special Conference
finance.yahoo.com - August 24 at 5:23 PM |
| Celsion Corp. :CLSN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:23 PM |
 | Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion
www.bizjournals.com - August 23 at 5:54 PM |
| Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion
www.bizjournals.com - August 23 at 5:54 PM |
| Edited Transcript of CLSN earnings conference call or presentation 15-Aug-17 3:00pm GMT
finance.yahoo.com - August 18 at 5:21 PM |
| Q3 2017 EPS Estimates for Celsion Corporation Increased by Griffin Securities (CLSN)
www.americanbankingnews.com - August 18 at 6:44 AM |
 | Celsion's (CLSN) CEO Michael Tardugno on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 15 at 11:01 PM |
| Celsion Corporation Reports Second Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - August 15 at 11:01 PM |
| Maxim Group Reiterates Hold Rating for Celsion Corporation (CLSN)
www.americanbankingnews.com - August 15 at 6:08 PM |
| Celsion Corporation Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 15 at 5:59 PM |
| Celsion Corporation (NASDAQ:CLSN) Releases Earnings Results
www.americanbankingnews.com - August 14 at 8:23 PM |
| Celsion Corporation to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 15, 2017 - GlobeNewswire (press release)
globenewswire.com - August 8 at 5:03 PM |
 | Celsion Corporation to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 15, 2017
feeds.benzinga.com - August 8 at 9:37 AM |
 | AQB Reaps A Bounty, CLSN Ends Dual Listing, MNK Opens Wallet ... - Nasdaq
www.nasdaq.com - August 8 at 3:46 AM |
 | Celsion (CLSN) Says DMC Completed Mid-Study Review of Phase III ThermoDox OPTIMA Study in Primary Liver Cancer - StreetInsider.com
www.streetinsider.com - August 8 at 3:46 AM |
| Celsion (CLSN) Says DMC Completed Mid-Study Review of Phase III ThermoDox OPTIMA Study in Primary Liver Cancer
www.streetinsider.com - August 7 at 5:43 PM |
| Celsion (CLSN) Says DMC Completed Mid-Study Review of Phase III ThermoDox OPTIMA Study in Primary Liver Cancer
www.streetinsider.com - August 7 at 5:43 PM |
| Data Monitoring Committee Completes Mid-Study Review of Celsion’s Phase III ThermoDox® OPTIMA Study in Primary Liver Cancer
finance.yahoo.com - August 7 at 5:43 PM |
| Data Monitoring Committee Completes Mid-Study Review of Celsion’s Phase III ThermoDox® OPTIMA Study in Primary Liver Cancer
finance.yahoo.com - August 7 at 5:43 PM |
| Maxim Group Reiterates Hold Rating for Celsion Corporation (NASDAQ:CLSN)
www.americanbankingnews.com - August 7 at 3:38 PM |
| Celsion Corporation to Delist from the Tel Aviv Stock Exchange - GlobeNewswire (press release)
globenewswire.com - August 4 at 10:38 PM |
| Celsion Corporation to Delist from the Tel Aviv Stock Exchange
finance.yahoo.com - August 4 at 10:38 PM |
| BUZZ-U.S. STOCKS ON THE MOVE- Apple, Systemax, Pioneer, AMC Entertainment
www.nasdaq.com - August 4 at 4:52 AM |
| Celsion Corporation (CLSN) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - August 3 at 7:16 AM |
| Celsion (CLSN) Reports Translational Data from OVATION Study in Newly Diagnosed Advanced Ovarian Cancer ... - StreetInsider.com
www.streetinsider.com - August 3 at 4:09 AM |
| Celsion (CLSN) Reports Translational Data from OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients
www.streetinsider.com - August 2 at 6:03 PM |
| Celsion Announces Latest Translational Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients
finance.yahoo.com - August 2 at 6:03 PM |
| Monday 7/10 Insider Buying Report: NYMX, CLSN
www.nasdaq.com - July 10 at 5:18 PM |
| Celsion Carves Itself A New Path
seekingalpha.com - July 10 at 5:18 PM |
| Today's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Celsion Corporation
finance.yahoo.com - July 8 at 9:49 AM |
| Celsion Corporation (NASDAQ:CLSN) Director Buys $24,570.00 in Stock
www.americanbankingnews.com - July 7 at 9:03 PM |
| Celsion Completes Ovarian Cancer Trial Enrollment, Stock Up - Nasdaq
www.nasdaq.com - July 7 at 4:36 AM |
| Celsion Corporation Announces $5 Million Registered Direct Offering - GlobeNewswire (press release)
globenewswire.com - July 7 at 4:36 AM |
| Celsion Corporation Announces $5 Million Registered Direct Offering
finance.yahoo.com - July 6 at 6:31 PM |
| Celsion Corporation (NASDAQ:CLSN) Expected to Announce Quarterly Sales of $130,000.00
www.americanbankingnews.com - July 6 at 9:28 AM |
| Celsion Announces Completion of OVATION Study and Provides Update on its Immunotherapy Trial in Advanced Stage III and IV Ovarian Cancer
finance.yahoo.com - July 5 at 11:01 PM |
| Mid-Afternoon Market Update: Crude Oil Down 3.8%; Monogram Residential Trust Shares Spike Higher - Benzinga
www.benzinga.com - July 5 at 5:58 PM |
| 12 Biggest Mid-Day Gainers For Wednesday | Benzinga - Benzinga
www.benzinga.com - July 5 at 5:58 PM |
| BUZZ-US STOCKS ON THE MOVE- Tesla, O'Reilly Automotive, Diebold Nixdorf - Nasdaq
www.nasdaq.com - July 5 at 5:58 PM |
| Celsion completes OVATION study and provides update on advanced stage III and IV Ovarian Cancer; shares ahead ... - Seeking Alpha
seekingalpha.com - July 5 at 5:58 PM |
| Celsion Corporation (CLSN) Expected to Post Earnings of -$1.18 Per Share
www.americanbankingnews.com - July 4 at 10:30 PM |
| Q1 2018 Earnings Estimate for Celsion Corporation (NASDAQ:CLSN) Issued By Griffin Securities
www.americanbankingnews.com - July 3 at 10:07 AM |
| Celsion Corporation (CLSN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - June 26 at 10:04 PM |
Celsion Corporation (CLSN) Chart for Tuesday, September, 26, 2017
